Silo Pharma Inc Stock Price, News & Analysis

Silo Pharma (Nasdaq: SILO) has strengthened its intellectual property portfolio with a new Japanese patent (No. 7683882) granted to its research partner Columbia University for SPC-15, the company's lead PTSD treatment. The patent, which follows a recent Australian patent grant, covers serotonin 4 receptor agonists for stress treatment.

The intranasal PTSD treatment, exclusively licensed to Silo by Columbia University, gains additional international protection through this patent issuance, supporting the company's development and regulatory strategy for this novel therapy.

Silo Pharma (Nasdaq: SILO) has secured a significant patent in Australia (patent number 2020271839) for its PTSD drug candidate SPC-15. The patent, granted to Silo's research partner Columbia University, covers the invention "Prophylactic efficacy of serotonin 4 receptor agonists against stress" which is exclusively licensed to Silo.

SPC-15, the company's lead asset, is being developed as an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent strengthens Silo's global intellectual property portfolio and supports their plans for clinical trial development of this innovative therapeutic approach to preventing stress-induced disorders.

Silo Pharma (Nasdaq: SILO) announced the publication of preclinical research for its Alzheimer's disease therapeutic SPC-14 in the prestigious journal Alzheimer's Research & Therapy. The study demonstrates that SPC-14, a combination of (R,S)-ketamine with prucalopride, showed promising results in treating cognitive decline in Alzheimer's disease.

The research, co-authored by CEO Eric Weisblum, revealed that SPC-14 improved memory retrieval in mouse models. The therapeutic was developed under a sponsored research agreement with Columbia University, from which Silo obtained an exclusive global license in 2024 for development, manufacturing, and commercialization. The targeted Alzheimer's disease treatment market is projected to reach $30.8 billion by 2033, growing at a 18.8% CAGR.

Silo Pharma (Nasdaq: SILO) announced positive safety results for its PTSD drug candidate SPC-15 in a FDA-requested 7-day large animal safety study. The intranasal spray formulation demonstrated local and systemic safety with no toxicities at clinical-representative doses, showing comparable systemic exposure to standard oral administration.

The company is pursuing FDA approval through the 505(b)(2) pathway, which could streamline the approval process by leveraging existing safety data. Silo is currently conducting IND-enabling GLP toxicology studies and evaluating clinical trial sites. The PTSD market, valued at $1.8 billion in 2024, is projected to reach $3.2 billion by 2034.

Silo Pharma (Nasdaq: SILO) has announced a strategic expansion into cryptocurrency treasury management, focusing on Bitcoin, Ethereum, and Solana. The company has appointed crypto infrastructure expert Corwin Yu as the first member of its new Crypto Advisory Board to spearhead this initiative.

The strategy includes opportunistic digital currency purchases and yield generation through staking, supported by newly acquired AI-powered market intelligence technology. Simultaneously, Silo Pharma continues its biopharmaceutical focus, with its PTSD drug SPC-15 approaching FDA IND application submission.

Silo Pharma (Nasdaq: SILO) has completed dosing in a FDA-requested 7-day safety and toxicology large animal study for its lead PTSD drug candidate SPC-15. The bioanalytical and safety/toxicology results are expected within 60 days.

The company is progressing with two remaining preclinical studies: an IND-enabling GLP-compliant toxicology study and a device study for SPC-15's microchip-based nasal spray system. Silo plans to pursue the FDA's 505(b)(2) regulatory pathway for SPC-15's approval, which could potentially accelerate clinical timelines and reduce development costs.

Silo Pharma (Nasdaq: SILO) announced significant progress in the development of SPC-15, its novel intranasal PTSD drug candidate. The company expects to receive crucial preclinical study data within 30-90 days, including results from GLP-compliant toxicology studies and an FDA-requested safety study.

The company plans to submit an IND application by end of 2025, potentially leading to Phase 1 clinical trials in 2026. Silo intends to pursue the FDA's 505(b)(2) regulatory pathway to expedite development. Notably, SPC-15's unique approach targets stress resilience, differentiating it from existing PTSD treatments, in a market where no new drugs have been approved in nearly 25 years.

Silo Pharma (NASDAQ:SILO) has entered into a non-binding letter of intent with Hoth Therapeutics (NASDAQ:HOTH) to form a 50:50 joint venture targeting the $16 billion global obesity market. The collaboration focuses on developing a novel therapeutic platform based on glial cell line-derived neurotrophic factor (GDNF), exclusively licensed from the U.S. Department of Veterans Affairs and co-developed with Emory University.

The technology, protected under U.S. Patent No. 10,052,362, targets multiple conditions including obesity, non-alcoholic fatty liver disease (NAFLD), and type 2 diabetes. The partnership combines Hoth's regulatory expertise with Silo's translational capabilities to address a significant unmet need, as obesity affects over 40% of U.S. adults, with veterans being particularly impacted.

Hoth Therapeutics (NASDAQ: HOTH) and Silo Pharma (NASDAQ: SILO) have formed a 50/50 joint venture to develop and commercialize a novel obesity treatment licensed from the U.S. Department of Veterans Affairs. The therapy is based on Glial Cell Line-Derived Neurotrophic Factor (GDNF), targeting obesity and non-alcoholic fatty liver disease (NAFLD).

The technology, protected under U.S. Patent No. 10,052,362, aims to address a $100B+ market with potential applications for type 2 diabetes and central obesity. The partnership combines the VA's clinical infrastructure, Hoth's regulatory expertise, and Silo's translational capabilities to develop this first-in-class treatment targeting the neuroinflammatory root of obesity.